Eli Lilly and Company: Colorectal Neoplasms trials
The registry lists 37 Colorectal Neoplasms studies with Eli Lilly and Company as lead sponsor. 4 are open to participants now and 15 have results posted.
Phase 1 17Phase 2 19Phase 3 3No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C MutationNot yet recruitingNCT07814417Phase 2
- A Study of LY4337713 in Participants With FAP-Positive Solid TumorsRecruitingNCT07213791Phase 1
- A Study of LY4257496 in Participants With Cancer (OMNIRAY)RecruitingNCT07114601Phase 1
- A Study of Sofe-M in Participants With Selected Advanced Solid TumorsRecruitingNCT06400472Phase 1
- A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C MutationTerminatedNCT04165031Phase 1/2Results posted
- A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their BodyTerminatedNCT02014116Phase 1Results posted
- A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsCompletedNCT02009449Phase 1Results posted
- A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)CompletedNCT01286818Phase 1Results posted
- A Study in Second Line Metastatic Colorectal CancerCompletedNCT01183780Phase 3Results posted
- A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and NeckCompletedNCT01059643Phase 2Results posted
- A Study of IMC-1121B (Ramucirumab) in Colorectal CancerCompletedNCT00862784Phase 2Results posted
- A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and BevacizumabTerminatedNCT00845039Phase 2Results posted
- Study of IMC-11F8 in Participants With Colorectal CancerCompletedNCT00835185Phase 2Results posted
- Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon CancerCompletedNCT00612586Phase 2Results posted
- Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR TherapyCompletedNCT00503685Phase 2Results posted
- A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal CancerCompletedNCT00437268Phase 2Results posted
- A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal CancerCompletedNCT00192075Phase 2Results posted
- A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal CancerCompletedNCT00191984Phase 2Results posted
- Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to ChemotherapyCompletedNCT00083720Phase 2Results posted
- A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsActive, not recruitingNCT06607185Phase 1
- MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid TumorsActive, not recruitingNCT06586515Phase 1
- FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)TerminatedNCT05432193Phase 1
- Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)Active, not recruitingNCT04956640Phase 1/2
- An Expanded Access Program for AM0010 (Pegilodecakin)No longer availableNCT03554434
- A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic CancerCompletedNCT02860780Phase 1
- A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic CancerCompletedNCT02857270Phase 1
- A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted AgentsCompletedNCT02745769Phase 1
- A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced CancerCompletedNCT02124148Phase 1
- A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal CarcinomaCompletedNCT00362102Phase 2
- An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal CancerCompletedNCT00207155Phase 1
- Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal CancerCompletedNCT00079872Phase 2
- Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal CancerCompletedNCT00063141Phase 3
- Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal CancerCompletedNCT00061815Phase 3
- A Study of Cetuximab in Patients Who Have Stage IV Colorectal CancerCompletedNCT00055419Phase 2
- Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal CarcinomaCompletedNCT00044863Phase 2
- A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.CompletedNCT00034619Phase 2
- A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.CompletedNCT00034502Phase 1/2